Ajanta Pharma

Pharma firms with India focus preferred as US market concerns grow

Steady outlook and higher returns triggers for companies refining their strategy

Lupin set to gain market share in US flu season; shares up 6% in 2 sessions

The stock has underperformed peers and the benchmark over the past year

Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore

Promoter entities of Ajanta Pharma on Thursday divested 4.3 per cent stake in the company for Rs 637 crore through open market transactions. The buyers included over two dozen funds such as UTI Mutual Fund (MF), Aditya Birla Sun Life MF, Franklin Templeton MF, ICICI Prudential MF, Mirae Asset MF, Abu Dhabi Investment Authority and Tata AIA Life Insurance Company, among others. Aayush Agrawal Trust and Ravi Agrawal Trust offloaded a total of 54,92,846 shares, amounting to 4.3 per cent stake in Ajanta Pharma, as per block deal data with the National Stock Exchange (NSE). The shares were offloaded at an average price of Rs 1,160.1 per scrip, taking the transaction value to Rs 637.22 crore. Following the stake sale, the promoter and promoter group entities' shareholding has come down to 66.18 per cent from 70.48 per cent. Ajanta Pharma's shares closed 5.22 per cent higher at Rs 1,233 apiece on NSE. Mumbai-based Ajanta Pharma is a speciality pharmaceutical formulation company.

Stocks to Watch: Adani Enterprises, Vi, Hero Moto, Amara Raja, Blue Star

Stocks to Watch: Vodafone India's net loss widened 6.4 per cent on a year-on-year (YoY) basis at Rs 7,595 crore in the second quarter of FY23 due to an increase in finance and operating expenses

Here's why Vinay Rajani recommends buying Ajanta Pharma, TTK Prestige

The technical analyst also recommends to hold Nifty longs with a stop at 16,300; on the upside, he expects resistance for the NSE benchmark around 16,800.

Ajanta Pharma extends fall, slips 2%; stock turned ex-bonus on Wednesday

The company had fixed June 23, 2022 as the record date for the bonus issue in the proportion of one equity share for every two equity shares held

Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4

In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.

Ajanta Pharma Q4 PAT falls 5% to Rs 151 cr; revenue rises to Rs 870 cr

Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.

Stocks to Watch: Textiles, Amara Raja, Airtel, TCS, ITC, Ajanta Pharma

Textiles shares shall be in limelight as the government has released the operational guidelines for the production-linked incentive (PLI) scheme

Ajanta Pharma board approves up to Rs 286-crore share buyback plan

Drug firm Ajanta Pharma said its board has approved a share buyback plan of up to Rs 286-crore, wherein the drug maker will buy back shares at a maximum price of Rs 2,550 apiece.

Ajanta Pharma gains 5% on share buyback plan, board to meet on Dec 28

The board of directors of the company is scheduled to consider a proposal for buy-back of equity shares on Tuesday, December 28.

Stocks to Watch: Data Patterns, Tega, LTFH, GMR Infr, Allcargo, Ajanta Phar

Data Patterns is likely to witness a bumper listing, with Grey Market Premium (GMP) indicating a likely 45-50 per cent premium to its issue price.

Ajanta Pharma second quarter profit rises 15% to Rs 196 crore

Shares of the company were trading 1.17 per cent down at Rs 2,102.80 apiece on the BSE

Nifty's short-term trend has turned bullish: Nandish Shah of HDFC Sec

Oscillators like RSI and MFI have broken out from the downward slopping trendline, indicating strength in Nifty's current rally

Ajanta Pharma zooms 8% to fresh 52-week high on strong Q3 results

Despite normalisation in fixed costs (at pre-Covid levels), the company's Ebitda margin came 372 bps higher YoY at 32 per cent, driven by improvement in gross margin

Ajanta Pharma trades firm in a subdued market as board mulls share buyback

In the past six months, Ajanta Pharma has underperformed the market by gaining 8.9 per cent against 26 per cent rally in S&P BSE Healthcare index

Weekly stock picks by Religare Broking: Buy Ajanta Pharma, Dabur India

Ajanta Pharma's stock has seen a fresh breakout from the trading range of roughly 1350-1480 levels

Buoyed by US revenues, higher growth trajectory awaits Ajanta Pharma

Completion of capex, improving prospects among positives

Market Wrap, Feb 6: Sensex gains 163 pts; PSBs, pharma stocks jump

Bharti Airtel has joined the elite club of Rs 3-trillion market capitalization as shares of the telecom services provider hit a new high of Rs 550

Ajanta Pharma surges 11% on strong Q3 performance, profit jumps 61% YoY

Revenue from operation stood at Rs 651 crore, up 34 per cent YoY while EBITDA grew 73 per cent YoY to Rs 186 crore.